0
Abstract: Poster Presentations |

SAFETY OF INHALED ILOPROST TAKEN LESS THAN SIX TIMES PER DAY IN PULMONARY ARTERIAL HYPERTENSION PATIENTS ON CONCOMINANT ORAL THERAPY FREE TO VIEW

Rajeev Saggar, MD*; Nick H. Kim, MD, FCCP; Sandee Lombardi, RN; Johanna Van Dijk, RN; Richard N. Channick, MD, FCCP
Author and Funding Information

Universtiy of California, San Diego Medical Center, La Jolla, CA



Chest. 2006;130(4_MeetingAbstracts):257S. doi:10.1378/chest.130.4_MeetingAbstracts.257S-c
Text Size: A A A
Published online

Abstract

PURPOSE: Inhaled iloprost (Ventavis) is approved for pulmonary arterial hypertension (PAH) at a dose of 5 ug 6-9 times per day. The purpose of this study was to determine compliance with the recommend dose, and to determine the safety and efficacy in patients using less than 6 inhalations per day of inhaled iloprost.

METHODS: Fifty-three patients with PAH who began inhaled iloprost between 2002 and 2006 were identified. Telephone interviews were attempted to assess compliance with dosing and adverse effects, and record review for clinical data was performed.

RESULTS: Twenty patients were successfully contacted by telephone and detailed interviews completed. All of these patients were on oral therapy prior to the initiation of iloprost (bosentan 13, bosentan + sildenafil 7). Median duration of iloprost use was 29.5 ± 10.5 weeks. Twelve of 20 patients were using inhaled iloprost at a dose frequency less than 6x/day. Median inhalations for these patients were 4/day. Reasons for less frequent inhalation in all 12 patients were lack of perceived need for more frequent use and lifestyle limitations. Two of the 12 perceived actual increased dyspnea with more frequent use. In this group, no episodes of syncope or clinical worsening were reported. None of the < 6x/day patients required treatments during the nighttime hours. All of these patients were NYHA class III at initiation of iloprost therapy. At the time of telephone interview, 5 of the <6x/day patients had improved to Class II.

CONCLUSION: Inhaled iloprost at a dose frequency less than the recommended 6-9/day is common in PAH patients and is not associated with adverse events or clinically apparent loss of efficacy.

CLINICAL IMPLICATIONS: Prospective studies are needed to confirm that use of inhaled iloprost at a dose frequency of less than 6 x/day is safe and efficacious.

DISCLOSURE: Rajeev Saggar, None.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543